- Home
- PCRX vs RERE Comparison
PCRX vs RERE Comparison
Compare PCRX & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- RERE
- Stock Information
- Founded
- PCRX 2006
- RERE 2011
- Country
- PCRX United States
- RERE China
- Employees
- PCRX N/A
- RERE N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- RERE Other Specialty Stores
- Sector
- PCRX Health Care
- RERE Consumer Discretionary
- Exchange
- PCRX Nasdaq
- RERE Nasdaq
- Market Cap
- PCRX 604.7M
- RERE 527.7M
- IPO Year
- PCRX 2011
- RERE 2021
- Fundamental
- Price
- PCRX $16.52
- RERE $2.40
- Analyst Decision
- PCRX Buy
- RERE
- Analyst Count
- PCRX 10
- RERE 0
- Target Price
- PCRX $26.60
- RERE N/A
- AVG Volume (30 Days)
- PCRX 545.3K
- RERE 602.7K
- Earning Date
- PCRX 11-06-2024
- RERE 11-20-2024
- Dividend Yield
- PCRX N/A
- RERE N/A
- EPS Growth
- PCRX N/A
- RERE N/A
- EPS
- PCRX N/A
- RERE N/A
- Revenue
- PCRX $694,957,000.00
- RERE $2,003,353,284.00
- Revenue This Year
- PCRX $4.59
- RERE $26.08
- Revenue Next Year
- PCRX N/A
- RERE $25.55
- P/E Ratio
- PCRX N/A
- RERE N/A
- Revenue Growth
- PCRX 4.40
- RERE 28.24
- 52 Week Low
- PCRX $11.16
- RERE $1.01
- 52 Week High
- PCRX $35.95
- RERE $3.19
- Technical
- Relative Strength Index (RSI)
- PCRX 44.28
- RERE 43.95
- Support Level
- PCRX $16.11
- RERE $2.30
- Resistance Level
- PCRX $18.34
- RERE $2.63
- Average True Range (ATR)
- PCRX 0.83
- RERE 0.10
- MACD
- PCRX -0.17
- RERE -0.01
- Stochastic Oscillator
- PCRX 5.33
- RERE 26.76
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.